225 programming-"https:"-"Inserm"-"FEMTO-ST" "https:" "https:" "https:" "https:" "UCL" uni jobs at Harvard University
Sort by
Refine Your Search
-
releases. Meet with users interested in using the LXP for their programs. Demo the product and answer questions about the product. Monitor and manage the queue for tickets related to LXP. Working Conditions
-
desired. Special Instructions Required materials, to be submitted through the ARIeS portal (https://academicpositions.harvard.edu/hr/postings/15712 ): 1. Cover letter 2. Curriculum Vitae 3. Writing sample
-
an inclusive community of dedicated problem-solvers who hold themselves - and one another - to the highest academic and professional standards. To learn more about us, please visit https://seas.harvard.edu
-
of disciplines—architecture, landscape architecture, urban planning and design, design engineering, real estate and housing—with an emerging research program and a robust public program of lectures and exhibition
-
written skills are required. Ability to plan and manage multiple projects with various stakeholders simultaneously is a must. Ability to perform independently as well as to collaborate with others is
-
Management Application Suite (GMAS), Harvard’s enterprise system of record for sponsored programs. Working in an Agile environment, the role provides opportunities to drive architectural design decisions, lead
-
necessary. Draft, issue, track, and release legal hold notices; monitor acknowledgments and compliance; maintain audit-ready logs Scope, plan, track, and execute targeted and large-scale data collections
-
interested in using the LXP for their programs. Demo the product and answer questions about the product. Monitor and manage the queue for tickets related to LXP. Working Conditions: Onsite work will be
-
timely proposal development, supporting major, principal, and institutional philanthropic initiatives of the Institute. Program Design and Development Identify and shape compelling engagement programs and
-
breakthroughs. We are on a mission to develop a first-in-class therapeutic antibody that has the promise to target a wide range of devastating metabolic diseases. As we prepare to advance our program to IND